Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, in what is believed to be the world's first reported completely ...

Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...

A novel nickel-free, low-profile TAVI valve shows promise in treating severe aortic stenosis, according to first-in-human ...

In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing ...

Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led ...

Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...

Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials. The data, presented at the annual New York Valves 2026 conference, included seven-year ...

The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the ...